Technical Analysis for LXEO - Lexeo Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Upper Bollinger Band Walk | Strength | -10.85% | |
| Wide Bands | Range Expansion | -10.85% | |
| Upper Bollinger Band Walk | Strength | -16.98% | |
| Wide Bands | Range Expansion | -16.98% | |
| Upper Bollinger Band Touch | Strength | -16.98% | |
| Stochastic Sell Signal | Bearish | -27.24% | |
| New 52 Week Closing High | Bullish | -27.24% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 5% | 2 days ago |
| Down 3% | 2 days ago |
| Fell Below Previous Day's Low | 2 days ago |
| Down 2 % | 2 days ago |
| Down 1% | 2 days ago |
Get a Trading Sidekick!
- Earnings date: Unknown
Lexeo Therapeutics, Inc. Description
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Rare Diseases Gene Therapy Applied Genetics Cardiomyopathy Lipid Storage Disorders Ataxia Friedreich's Ataxia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.5 |
| 52 Week Low | 9.0 |
| Average Volume | 130,262 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 12.16 |
| 10-Day Moving Average | 13.38 |
| Average True Range | 1.39 |
| RSI (14) | 48.19 |
| ADX | 0.0 |
| +DI | 27.18 |
| -DI | 23.16 |
| Chandelier Exit (Long, 3 ATRs) | 13.33 |
| Chandelier Exit (Short, 3 ATRs) | 13.49 |
| Upper Bollinger Bands | 15.59 |
| Lower Bollinger Band | 8.74 |
| Percent B (%b) | 0.42 |
| BandWidth | 56.38 |
| MACD Line | 1.16 |
| MACD Signal Line | 1.00 |
| MACD Histogram | 0.1583 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.12 | ||||
| Resistance 3 (R3) | 14.30 | 13.62 | 13.70 | ||
| Resistance 2 (R2) | 13.62 | 12.98 | 13.54 | 13.56 | |
| Resistance 1 (R1) | 12.61 | 12.58 | 12.27 | 12.43 | 13.42 |
| Pivot Point | 11.93 | 11.93 | 11.77 | 11.85 | 11.93 |
| Support 1 (S1) | 10.92 | 11.29 | 10.58 | 10.75 | 9.76 |
| Support 2 (S2) | 10.24 | 10.89 | 10.16 | 9.62 | |
| Support 3 (S3) | 9.23 | 10.24 | 9.48 | ||
| Support 4 (S4) | 9.06 |
